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Summary
We showed in this study that cells deficient of the BRCA1-associated BACH1 helicase, also known as BRIP1, failed to elicit
homologous recombination (HR) after DNA double-stranded breaks (DSBs). BACH1-deficient cells were also sensitive to
mitomycin C (MMC) and underwent MMC-induced chromosome instability. Moreover, we identified a homozygous non-
sense mutation in BACH1 in a FA-J patient-derived cell line and could not detect BACH1 protein in this cell line. Expression
of wild-type BACH1 in this cell line reduced the accumulation of cells at G2/M phases following exposure to DNA crosslink-
ers, a characteristic of Fanconi anemia (FA) cells. These results support the conclusion that BACH1 is FANCJ.S I G N I F I C A N C E
A functional link between BRCA1 and Fanconi anemia proteins has been controversial. The putative identification of the BRCA1-
associated helicase, BACH1, as FANCJ suggests that BACH1 could link BRCA1 to the FA pathway. In addition to a role for BACH1 in
breast cancer, we predict a wider role for BACH1 in disease mechanisms, including the bone marrow failure and predisposition to
leukemia associated with Fanconi anemia. These results suggest that BACH1 may function as a FA gene product by a direct role
in HR. Determination of the mechanistic relationship of BACH1 to other FA gene products now becomes an important topic for
future investigation.Introduction
DNA repair pathways are critical for the maintenance of geno-
mic stability, and defects in these processes are frequently as-
sociated with cancer. For example, inheritance of germline
mutations that affect one allele of either of the breast cancer
susceptibility gene products, BRCA1 or BRCA2, confers suscep-
tibility to breast and ovarian cancer. In the absence of func-
tional BRCA proteins, cells are sensitive to DNA-damaging
agents, and exhibit spontaneous and DNA damage-induced
chromosomal aberrations (Venkitaraman, 2002). Additionally,
numerous chromosomal fragility disorders are associated with
cancer susceptibility (Thompson and Schild, 2002). Among
these is Fanconi anemia. FA is associated with chromosome
instability, both spontaneously and in response to DNA cross-
linkers such as MMC, and also with an increased risk of leuke-
mia and other cancers (Grompe and D’Andrea, 2001).
Unlike BRCA1- or BRCA2-associated breast cancer, FA is a
multigenic disorder, with at least eleven distinct complementa-
tion groups (Venkitaraman, 2004). Nine FA genes have been
cloned, but FANCI and FANCJ, which are associated with the
FA-I and FA-J complementation groups, respectively, have re-
mained unidentified (Levitus et al., 2004). The FA proteins areCANCER CELL : SEPTEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIEorganized into a pathway in which a complex that includes
seven of the identified FA gene products, FANC-A, -B, -C, -E,
-F, -G, and -L, are required for the monoubiquitination of the
FA protein, FANCD2 (Garcia-Higuera et al., 2001). Monoubiqui-
tination of FANCD2 is required for resistance to MMC, mainte-
nance of chromosome stability, and assembly of FANCD2 foci,
which colocalize with proteins such as BRCA1 and Rad51 fol-
lowing exposure to DNA damage (Garcia-Higuera et al., 2001;
Montes de Oca et al., 2005; Taniguchi et al., 2002). Neither
FANCD1, which is BRCA2 (Howlett et al., 2002), nor FANCJ is
required for FANCD2 monoubiquitination, either with or without
exposure to DNA damage (Howlett et al., 2002; Levitus et al.,
2004; Wang et al., 2004). Consequently, it has been suggested
that BRCA2/FANCD1 and FANCJ function downstream in the
FA pathway, following activation of FANCD2 by monoubiquiti-
nation.
In addition to the identification of BRCA2 as the FA gene,
FANCD1 (Howlett et al., 2002), other observations suggest a
potential relationship between BRCA and FA proteins. Among
these, deficiency in either BRCA1 or BRCA2 results in hyper-
sensitivity to MMC, similar to that observed in FA cells (Howlett
et al., 2002; Moynahan et al., 2001; Ohashi et al., 2005; Yun et
al., 2005). Also, BRCA1 is required for FANCD2 foci formationR INC. DOI 10.1016/j.ccr.2005.08.004 255
A R T I C L E(Vandenberg et al., 2003), and BRCA1 was shown to immuno-
precipitate (IP) with FANCD2 in DNA-damaged cells (Garcia-
Higuera et al., 2001). Moreover, BRCA1 and BRCA2 colocalize
with FANCD2 in DNA damage-induced foci (Garcia-Higuera et
al., 2001; Wang et al., 2004). But, whether BRCA1 is required
for DNA damage-induced FANCD2 monoubiquitination has
been controversial (Garcia-Higuera et al., 2001; Vandenberg et
al., 2003).
Several lines of evidence indicate that the BRCA and FA
pathways influence HR-mediated DNA repair. BRCA1 and
BRCA2-deficient cells are defective for DSB-induced HR (re-
viewed in Scully and Livingston, 2000; Venkitaraman, 2002).
Likewise, in chicken DT40 cells, fancc, fancg, and fancd2 mu-
tants show reduced HR (Niedzwiedz et al., 2004; Yamamoto et
al., 2003, 2005). DNA damage that activates HR can be mea-
sured by the induction of Rad51 foci (Saintigny et al., 2001).
Deficiency of BRCA1 or BRCA2 attenuates the DNA damage-
inducible assembly of Rad51 foci (Bhattacharyya et al., 2000;
Tutt et al., 2001). It has been proposed that through mono-
ubiquitination of FANCD2, FA proteins serve to stabilize broken
replication forks, making Rad51-mediated recombination more
efficient (Thompson et al., 2005). While the specific contribu-
tion of FA proteins to HR is not clear, it appears that FANCD2
monoubiquitination is required for efficient HR (Nakanishi et al.,
2005; Venkitaraman, 2004; Yang et al., 2005).
The BRCA1 associated C-terminal helicase, BACH1 (also
known as BRIP1), which was identified by its direct binding to
the BRCA1 BRCT domains, was shown to participate in DNA
double-stranded break repair (DSBR) with BRCA1 (Cantor et
al., 2001). In this report, we have generated mammalian cells
in which expression of BACH1 has been suppressed to better
characterize the role of BACH1 in the DNA damage response.
We provide direct evidence that BACH1 is critical for the repair
of DNA double-stranded breaks (DSBs) by HR. BACH1-defi-
cient cells are defective for HR, hypersensitive to MMC, and
display increased levels of MMC-induced chromosomal insta-
bility, suggesting a potential relationship to the FA pathway.
Indeed, we find that a FA-J cell line lacks detectable BACH1
protein and maintains a biallelic truncating mutation in BACH1.
Further, we find that FA-J cells, like other FA cells, display a
pronounced G2/M accumulation following exposure to DNA in-
terstrand crosslinkers (Chandra et al., 2005; Dutrillaux et al.,
1982; Heinrich et al., 1998; Kaiser et al., 1982; Kupfer and
D’Andrea, 1996; Kupfer et al., 1997), and this phenotype is cor-
rected by expression of BACH1. Together, these results sug-
gest that BACH1 is the FANCJ gene product functioning in HR
downstream of FANCD2.
Results
HR is disrupted in BACH1-deficient cells
BACH1 function in DSBR was identified by the finding that
overexpression of a helicase dead version of BACH1 delayed
DSBR kinetics (Cantor et al., 2001). To more directly address
the role of BACH1 in DSBR, we examined the biological conse-
quence of BACH1 deficiency on the repair of DSBs by HR.
Using a similar assay system in which BRCA1 has been shown
to support HR (Moynahan et al., 1999), we examined the ability
of BACH1-deficient cells to support HR in response to DSBs.
We established an MCF7 cell line with an integrated copy of
the pDR-GFP reporter as described previously (Pierce et
al., 1999). Puromycin-resistant cell lines were isolated and
screened for the ability of an I-Sce1 induced DSB to generate256HR. If HR occurs, GFP is expressed and GFP-positive cells can
be quantified by flow cytometry (Pierce et al., 1999). Twenty-
four hours after transfection with short interfering RNAs (siRNA)
targeting BACH1 or BRCA1, the MCF7 DR-GFP cells were
subsequently transfected with pCMV-I-Sce1. MCF7 DR-GFP
cells transfected with luciferase (luc) siRNA then with pCMV-I-
Sce1 were used as a control. Three days after I-Sce1 transfec-
tion, the cells were analyzed by flow cytometry to determine
the percentage of green fluorescent cells relative to the total
cell number. Transient transfection of the I-Sce1 endonuclease
demonstrated that MCF7 DR-GFP cells exhibit I-Sce1 induc-
ible HR, producing GFP-positive cells quantified by flow cy-
tometry (Figure 1A). In BRCA1- or BACH1-deficient cells, the
percentage of I-Sce1-induced GFP-positive cells was greatly
reduced compared to control cells. The I-Sce1 induction of
GFP-positive cells (w0.5%) was similar to what has been ob-
served previously (Moynahan et al., 2001). In contrast, the
I-Sce1 induction in cells with BACH1 siRNA led to an average
of w0.048% cells that were positive for GFP, which is w10
fold lower than the GFP-positive cells containing the luc control
siRNA (average p value .00051) (Figure 1B). The number of
GFP-positive cells were reduced to 0.07%, that is, w7-fold
lower in cells with siRNA to BRCA1, as compared to luc con-
trols (p value .00029) (Figure 1B). The siRNA-mediated sup-
pression of BACH1 and BRCA1 was specific to their respective
target proteins, whereas siRNA directed against luc had no ef-
fect on the levels of BACH1 or BRCA1 protein (Figure 1C). The
overall transfection efficiency with pCMV-I-Sce1 was not af-
fected by the siRNA transfection (data not shown). These re-
sults demonstrate that BRCA1 and BACH1 deficiency lead to
a defect in DSBR by HR.
BACH1-deficient cells are sensitive to MMC
The reduction in HR frequency in BACH1-deficient cells
prompted us to test whether BACH1-deficient cells were also
sensitive to MMC. MMC induces DNA interstrand crosslinks,
which are repaired by a mechanism relying in part on HR
(Thompson et al., 2005). To examine the effects of MMC treat-
ment, we suppressed BACH1 protein expression with BACH1
siRNA. Previous reports have demonstrated that BRCA1-defi-
cient cells are sensitive to MMC (Moynahan et al., 2001; Yun
et al., 2005). Thus, we also suppressed BRCA1 protein expres-
sion with siRNA to compare the effects of MMC on survival in
BACH1- or BRCA1-deficient cells. Transfection of MCF7 cells
with the BACH1 or BRCA1 siRNA led to substantial reduction
of BACH1 or BRCA1 protein levels, respectively, as compared
to control cells transfected with luc siRNA. Transfections with
these siRNA did not induce detectable alterations of β-actin
protein levels (Figure 2B). Photometric assays showed that
BACH1 and BRCA1-deficient cells were extremely sensitive to
MMC as compared to control cells (Figure 2A). Representative
results from one of three independent experiments are shown
in which the SF50 (dosage at which 50% of cells survived) for
MMC was w10–100 nM for BACH1- and BRCA1-deficient
MCF7 cells, as compared to 1000 nM for MCF7 cells trans-
fected with luc siRNA. Similar MMC sensitivity results were ob-
tained with suppression of BACH1 or BRCA1 in HEK cells (data
not shown).
In order to determine whether MMC led to chromosomal ab-
normalities in BACH1-deficient cells, we compared BACH1-
deficient and control cells treated with 100 nM MMC for fourCANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 1. BACH1-deficient cells have a defect in DSB-induced HR
Gene conversion of the pDR-GFP construct by HR is observed as GFP positive cells. The percentage of cells with I-SceI induced HR events was quantitated
by flow cytometry in MCF7 DR-GFP cells, also transiently transfected with either BACH1 (reagent A or reagent B), BRCA1, or luciferase siRNA.
A: Representative flow cytometric profiles of viable MCF7 DR-GFP cells transfected with the indicated siRNA reagents.
B: Percent GFP-positive cells are indicated for each siRNA reagent, with standard deviation based on three independent experiments. P values were
calculated using the Student’s t test (p = .00051 and .00029 for BACH1 and BRCA1, respectively). A total of 250,000 events were analyzed for each
experiment, and experiments were performed in triplicate.
C: Western blot of whole cell extracts was prepared from MCF7 DR-GFP treated with indicated siRNA using indicated antibodies.days. For these experiments, shRNA lentiviral vectors targeting
BACH1 (Reagent A) or enhanced green fluorescent protein
(eGFP), used as a control, were designed and used to infect
HMEC cells. BACH1 protein level was efficiently reduced in
cells expressing BACH1 shRNA (Figure 2D). BACH1 deficiency
led to chromatid breaks and more complex chromatid aber-
rations such as triradial and quadriradial chromosomes. At the
same dose, such aberrations were rarely seen in control eGFP
shRNA HMEC cells (Figure 2C). These findings suggest that
BACH1 deficiency leads to a failure to repair DSBs by HR. As
suggested previously, other mechanisms to repair DSBs, such
as single-stranded annealing and/or nonhomologous end join-
ing, most likely fail to maintain chromosome integrity (Bryant
et al., 2005; Farmer et al., 2005).
DNA damage-induced FANCD2 monoubiquitination and
Rad51 foci formation are intact in BACH1-deficient cells
Inactivation of BACH1 yields defects in HR, hypersensitivity to
MMC, and increased MMC-induced chromosome instabilityCANCER CELL : SEPTEMBER 2005similar to inactivation of FA genes (Grompe and D’Andrea,
2001; Nakanishi et al., 2005; Yamamoto et al., 2003). This sug-
gested a possible relationship of BACH1 to the FA pathway,
although inactivation of genes that have not been identified as
FA genes, such as BRCA1 and Rad51, also results in similar
defects (Moynahan et al., 2001; Stark et al., 2002; Yun et al.,
2005). To pursue the relationship of BACH1 to the FA pathway,
we investigated whether BACH1 function was required for
FANCD2 monoubiquitination. FANCD2 monoubiquitination, as
identified by a hydroxyurea (HU)-induced increase in a form of
FANCD2 which migrates slower by SDS-PAGE (FANCD2-L),
was the same in BRCA1- and BACH1-deficient cells as in con-
trol cells infected with shRNA to eGFP (Figure 3A). Suppression
of protein expression by shRNA is shown (Figure 3C). In con-
trast, FA-A (PD6914) cells do not support FANCD2 monoubiq-
uitination unless reconstituted with the FANCA gene, as pre-
viously reported (Garcia-Higuera et al., 2001; Yang et al., 2005).
FA-D2 cells served as a negative control for the Western blot257
A R T I C L EFigure 2. BACH1-deficient cells are sensitive to
MMC
A: MCF7 cells transfected with luciferase siRNA
(diamonds), BRCA1 siRNA (squares), or BACH1
siRNA (triangles) were treated with increasing
concentrations of MMC. Cell growth was mea-
sured by ATP content after 4–5 days of MMC ex-
posure. Experiments were performed in triplicate,
and a representative experiment is shown.
B: Effects of siRNA on protein expression in MCF7
cells are shown by Western blot.
C: HMEC cells containing shRNA to either eGFP
or BACH1 were untreated (left) or treated (right)
with 100 nM of MMC, and genetic instability was
analyzed by chromosome spreads. Representa-
tive defects from various BACH1-deficient cells
treated with MMC are shown on far right: a,
chromosome break; b, quadriradial; and c, tri-
radial. Arrow shows a radial chromosome.
D: Effects of shRNA on BACH1 protein expression
in HMEC cells are shown by Western blot.is defective in FANCD1 cells expressing C-terminally truncated
Figure 3. BACH1 is dispensable for FANCD2
monoubiquitination and Rad51 foci formation
after DNA damage
A: FANCD2 protein in whole cell lysates from un-
treated or HU-treated (24 hr) MCF7 cells trans-
duced with lentivirus expressing indicated shRNA
was detected by Western blot. FA-A (a FANCA
mutant cell line PD6914) and FA-A+FANCA cells
(PD6914 expressing wild-type FANCA) were
used as negative and positive controls for
monoubiquitination of FANCD2. FA-D2 (a
FANCD2 mutant cell line PD20) served as a
negative control for the FANCD2 Western blot.
FANCD2-L and FANCD2-S represent monou-
biquitinated and nonubiquitinated FANCD2, re-
spectively. Asterisk (*) denotes a nonspecific
band present in all cell lines analyzed, including
PD20 cells lacking FANCD2.
B: MCF7 cells containing shRNA for eGFP,
BRCA1, or BACH1 were treated with 1 mM HU
for 18 hr and stained with either γ-H2AX or Rad51
antibody as indicated, or with 4#,6-diamidino-2-
phenylindole (DAPI).
C: Western blot analysis of BACH1, BRCA1, and
β-actin in whole-cell lysates from MCF7 cells ex-
pressing indicated shRNA.
foci were present in both BACH1-deficient cells and in controlanalysis, since they lack FANCD2 protein (Garcia-Higuera et
al., 2001) (Figure 3A). FANCD2 monoubiquitination was also
intact in HeLa cells in which BACH1 was suppressed with
siRNA (data not shown).
The formation of Rad51 foci is critical for efficient HR (Venki-
taraman, 2004). DNA damage-induced assembly of Rad51 foci258BRCA2 (Godthelp et al., 2002; Wang et al., 2004) and in
BRCA1-deficient cells (Bhattacharyya et al., 2000). Based on
the finding that HR was defective in BACH1-deficient cells, we
hypothesized that similar to BRCA1-deficient cells, DNA dam-
age-induced Rad51 foci would be diminished in BACH1-defi-
cient cells. However, in response to HU, we found that RAD51CANCER CELL : SEPTEMBER 2005
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deficient for BRCA1 treated with HU (Figure 3B). Similar results
were obtained in MCF7 BACH1 siRNA cells treated with MMC,
as well as in BACH1-deficient SKOV3 cells treated with HU
(Supplemental Figure S1). The fact that Rad51 foci form in
BACH1-deficient cells suggests that BACH1 functions inde-
pendently of BRCA1 and potentially downstream of Rad51
(Figure 3B). In contrast, γ-H2AX foci form normally in both
BRCA1- and BACH1-deficient cell lines following treatment
with HU (Figure 3B). This suggests that the DNA damage re-
sponse is initiated normally in the absence of BACH1.
FANCJ cells lack detectable BACH1 protein expression
and contain a biallelic BACH1 truncating mutation
There are two FA complementation groups in which the gene
defect is not currently known. Given our findings that BACH1
functions in the HR pathway and is likely to be downstream of
FANCD2, we considered whether BACH1 is the gene defective
in the FA-J complementation group. To test this possibility, we
analyzed cell extracts from MCF7, hTERT immortalized normal
(PD846F), or FA-J (AG656) fibroblasts for BACH1 protein ex-
pression. Unlike the MCF7 and normal cells, full-length BACH1
was not detected in FA-J cells (Figure 4A). Moreover, IP with two
different BACH1 antibodies, or pulldown with the GST-BRCT fu-
sion protein that binds directly to the serine 990 region of
BACH1 (Yu et al., 2003), failed to precipitate full-length BACH1
in the FA-J cells (Figure 4B). Western blot analysis using the
I82 Ab, which was a polyclonal antibody generated using the
full-length BACH1 protein, did not reveal any detectable
BACH1 species in cell extracts or in IP experiments (data not
shown). Consistent with the possibility that BACH1 is the gene
defective in FA-J cells, FA-J cells maintained Rad51 and γ-H2AX
foci after HU treatment (Supplemental Figure S1), similar to theFigure 4. BACH1 protein expression is absent
from a patient-derived FA-J cell line
A: Whole cell lysates from MCF7, PD846F (nor-
mal), and AG656 (FA-J) cells were probed with
BACH1 and β-actin Abs.
B: BACH1 in cell lysates prepared from PD846F
and AG656 cells was immunoprecipitated using
I82 (lanes 1 and 3) or E67 antibody (lanes 2 and
4), or precipitated using GST-BRCT (lanes 5 and
6), and was then detected by Western blot
using the BACH1 antibody E87.
C: A schematic representation of the BACH1
coding region shows the PCR products created
by the specified primer sets (top). Roman nu-
merals show the relative location of the con-
served helicase motifs in the helicase domain
(dark blue). RT-PCR was performed on FA-J cells
using overlapping primers sets, and cDNA prod-
ucts were analyzed by gel electrophoresis
(bottom).
D: Mutations in the BACH1 gene in the FA-J cell
line AG656 were confirmed by direct DNA se-
quencing. The chromatograms shown indicate
a C-to-T point mutation at nt2392 (above), and
a polymorphism at nt2757 (below). Together, this
indicates a biallelic mutation of BACH1 at
nt2392 in this human FA-J cell line.CANCER CELL : SEPTEMBER 2005MCF7 cells in which BACH1 was suppressed with shRNA (Fig-
ure 3B).
We then investigated whether BACH1 was mutated in the
FA-J cells. RNA from the FA-J cells was purified, and RT-PCR
was performed using a series of BACH1 sequence primer sets
(Experimental Procedures). The RT-PCR generated the ex-
pected size products as determined using agarose gel electro-
phoresis (Figure 4C). These products were then purified from
the agarose gel and subjected to DNA sequencing analysis. A
C-to-T alteration was identified at nucleotide 2392 in exon 17
(Figure 4D). This alteration changes the codon 798 from CGA
encoding for arginine to a stop codon, TGA. This BACH1 muta-
tion has not previously been reported. The remainder of the
sequence was intact and read as a homozygous sequence ex-
cept at nucleotide 2755, in which both a T and a C were de-
tected (Figure 4D). This polymorphism at nucleotide 2755 has
previously been reported (Cantor et al., 2001). The point muta-
tion at nucleotide 2392 was confirmed by sequencing genomic
DNA (Supplemental Figure S3). The identification of both a C
and a T at nucleotide 2755 indicates that the FA-J cells used
in this study contain two alleles of the BACH1 gene and that
both alleles contain a C-to-T mutation at nucleotide 2392.
BACH1 cDNA corrects interstrand crosslink-induced
G2/M accumulation in FA-J cells
Characteristically, FA cells show an increased accumulation in
G2/M following exposure to DNA interstrand crosslinkers
(Chandra et al., 2005; Dutrillaux et al., 1982; Heinrich et al.,
1998; Kaiser et al., 1982; Kupfer and D’Andrea, 1996; Kupfer
et al., 1997). Consistent with this finding, we found that FA-J
cells accumulated in G2/M after treatment with the interstrand
crosslinker, melphalan. In contrast, this accumulation in G2/M
was not detected in the normal cells (PD846) (Figure 5A). Next,259
A R T I C L EFigure 5. Restoration of BACH1 cDNA corrects the melphalan-induced
G2/M accumulation of FA-J cells
A: PD846F (normal), FA-J, FA-J + vector, and FA-J + WT BACH1 cells were
either mock treated or treated with 0.5 g/ml melphalan for 65 hr. Cells
were then collected, stained with propidium iodide, and analyzed by flow
cytometry to assess DNA content. Three independent experiments were
performed and a representative experiment is shown.
B:Western blots confirm BACH1 expression in FA-J cells infected with lentivi-
rus expressing WT BACH1.we stably infected FA-J cells with cDNA encoding the full-
length wild-type BACH1 protein (Yu et al., 2003) using lentiviral
infection (Figure 5B). To test the ability of wild-type BACH1
cDNA to correct FA-J G2/M accumulation, we treated FA-J
+vector or FA-J +BACH1 with melphalan. The FA-J + vector
cells had an increase in G2/M content similar to the parental
FA-J cells, 46.3% and 45.4% respectively. Whereas, in FA-J +260BACH1 cells G2/M accumulation was decreased to 28.2%
(Figure 5A). The G2/M accumulation generated in FA-J cells
with MMC was also corrected with BACH1 cDNA (data not
shown). A comparable correction of the accumulation of FA-C
cells in G2/M was obtained by reintroduction of FANCC cDNA
(Kupfer and D’Andrea, 1996) and recently this correction of
mephalan-induced G/M accumulation was demonstrated by
reconstitution of FA cells with their respective FA cDNAs
(Chandra et al., 2005). Taken together, these results indicated
that BACH1 is the FANCJ gene.
Discussion
In this study, we have characterized the role of BACH1 in HR-
mediated DSBR using mammalian cells deficient for BACH1.
BACH1 was first identified by its interaction with the BRCT do-
main of BRCA1 (Cantor et al., 2001). Consistent with the possi-
bility that the interaction of BACH1 and BRCA1 is of functional
significance, we find that HR repair stimulated by DSBs is com-
promised in both BACH1-deficient cells and BRCA1-deficient
cells. Further supporting a role for BACH1 in HR-dependent
repair, BACH1-deficient cells, like BRCA1-deficient and FA
cells, are extremely sensitive to MMC (Howlett et al., 2002;
Moynahan et al., 2001; Ohashi et al., 2005; Yun et al., 2005).
BACH1 deficiency also results in increased MMC-induced
chromosome damage, suggesting a possible relationship to
the FA pathway. Analysis of human FA patient-derived cells
and deletion of various FA genes in chicken DT40 cells has led
to the conclusion that FA genes also function in HR (Hirano
et al., 2004; Nakanishi et al., 2005; Niedzwiedz et al., 2004;
Yamamoto et al., 2003, 2005).
FANCD2 monoubiquitination, the central feature of the FA
pathway (D’Andrea and Grompe, 2003; Garcia-Higuera et al.,
2001), is unaffected in BACH1-deficient cells. This is of interest
since there are two FA complementation groups in which
FANCD2 monoubiquitination, either spontaneously or in re-
sponse to DNA damage, is not compromised. One of these
groups is FA-D1, in which BRCA2/FANCD1 is mutated (Howlett
et al., 2002; Wang et al., 2004). BRCA2 has an important func-
tion in HR, and appears to regulate the assembly of the Rad51
filament involved in strand invasion (Davies et al., 2001; Pelle-
grini et al., 2002). The other FA complementation group in
which FANCD2 monoubiquitination is normal is FA-J (Levitus
et al., 2004), for which the defective gene, FANCJ, had not
been previously identified. Our results suggest that BACH1 is
FANCJ, since BACH1 protein is not detectable in FA-J cell ly-
sates, a homozygous BACH1 truncating mutation was iden-
tified in FA-J cells, and expression of wild-type BACH1 cor-
rects the drug-induced G2/M accumulation found in FA-J cells.
These results suggest that BACH1/FANCJ and BRCA2/
FANCD1 have critical functions in HR downstream of FANCD2
monoubiquitination.
Since FANCD2 monoubiquitination is normal in FA-J cells
(Levitus et al., 2004), it would appear that BACH1/FANCJ func-
tions independently of the seven identified FA proteins that are
present in the FA nuclear complex required for FANCD2 mono-
ubiquitination (Garcia-Higuera et al., 2001; Meetei et al., 2003,
2004) and downstream of monoubiquitinated FANCD2, like
BRCA2/FANCD1. Potentially consistent with this possibility, we
find that BACH1 and FANCD2 show partial colocalization after
treatment with MMC (data not shown). However, we also findCANCER CELL : SEPTEMBER 2005
A R T I C L Ethat BACH1 and FANCD2 do not coimmunoprecipitate before
or after DNA damage (data not shown). Understanding the
functional relationship of BACH1/FANCJ to other FA proteins
will be an important focus of future work.
Our inability to detect a truncated BACH1 protein by Western
blot analysis suggests that this truncated BACH1 species is
not stably expressed in the FA-J cells. Mutations of FANCA
predicted to yield premature truncation and an absence of
FANCA protein are frequently found in human FA-A patients
(Wijker et al., 1999; Adachi et al., 2002). Alternatively, the Ab
reagent used to detect BACH1 may lack the appropriate epi-
topes to efficiently bind the truncated BACH1 species.
Interestingly, BACH1 and BRCA1 function are distinct with
respect to their relationship to Rad51 foci. In BRCA1-deficient
cells, as previously reported (Bhattacharyya et al., 2000), we
found that Rad51 foci are greatly diminished, placing BRCA1
upstream of Rad51 in the HR pathway. In contrast, we found
that DNA damage-induced Rad51 foci formation was main-
tained in BACH1-deficient cells. Similarly, fancd2 mutant DT40
cells are deficient for DSB-initiated HR, but Rad51 foci forma-
tion was shown to be intact after MMC treatment (Yamamoto
et al., 2005). Still, it is possible that the assembly of RAD51
foci may merely be delayed in BACH1-deficient cells, so ex-
amination of the kinetics of the assembly of RAD51 foci in
these cells will be necessary to completely exclude the possi-
bility that BACH1 may regulate RAD51 assembly.
Our results suggest that there is no correlation between the
capacity for I-Sce1-induced HR and Rad51 foci formation. This
is also supported by results obtained by deletion of fancd2 in
DT40 cells (Yamamoto et al., 2005). We conclude that unlike
BRCA1, BACH1 is dispensable for the assembly of Rad51 foci
in response to DNA damage. Importantly, the DNA damage-
induced assembly of Rad51 foci is greatly diminished in FA-D1
cells expressing C-terminally truncated BRCA2/FANCD1 (God-
thelp et al., 2002; Wang et al., 2004). Because Rad51 foci for-
mation is normal in an FA-J cell line (Supplemental Figure S1),
and in cells in which BACH1 has been suppressed (Figure 3),
BRCA2/FANCD1 and BACH1/FANCJ likely have distinct func-
tions in the FA pathway.
During genetic recombination and the recombinational repair
of chromosome breaks, DNA molecules become linked at
points of strand exchange. Branch migration and resolution of
these crossovers, or Holliday junctions (HJs), completes the
recombination process. While BACH1 demonstrates no ability
to unwind HJ substrates in vitro (Cantor et al., 2004; Gupta et
al., 2005) like BLM or WRN helicases (Mohaghegh et al., 2001),
BACH1 binds HJ substrates (S.B.C., unpublished data). Given
that BLM is a suppressor of HR (Onclercq-Delic et al., 2003;
Sengupta et al., 2003), one possibility is that BACH1 could pro-
mote HR by blocking the access of BLM to the HJ and prevent
BLM from unwinding the HJ substrate. Alternatively, BACH1
could promote branch migration similar to the E. coli RuvA pro-
tein. After strand invasion and the formation of the HJ, RuvA
(a HJ-specific DNA binding protein) recruits RuvB, which pro-
motes branch migration. Similar to RuvA, BACH1 could serve
as a scaffold for assembly of other proteins and/or promote
branch migration of the HJ.
Alternatively, BACH1 could participate in processes that af-
fect the dynamics of Rad51 filament extension and disassem-
bly, like the Srs2 helicase in yeast. Mutants of the Srs2 helicase
display enhanced Rad51 foci, as the Srs2 helicase preventsCANCER CELL : SEPTEMBER 2005recombination by disrupting Rad51 nucleoprotein filaments on
single-stranded DNA (Veaute et al., 2003). We have shown that
BACH1 deficiency disrupts HR without disrupting the assem-
bly of DNA damage-induced Rad51 foci. Thus, BACH1 could
function in HR by disrupting Rad51 nucleoprotein filaments
and promote HR by enabling recycling of Rad51 for subse-
quent rounds of HR. If so, in BACH1-deficient cells, Rad51
could be locked on DNA. Given that BACH1 unwinds in a 5#-
3# direction, relative to the DNA to which it is bound (Cantor et
al., 2004; Gupta et al., 2005), and Rad51 filaments extend in
a 5#-3# direction relative to the single-stranded gap, BACH1
unwinding could directly serve to strip Rad51 protein filaments
upon completion of HR.
The development of gross chromosomal abnormalities in
MMC-treated BACH1-deficient cells supports the role of
BACH1 in maintaining chromosome stability. The sensitivity of
BACH1-deficient cells to MMC is most likely due to an over-
load of DNA damage that forces cells to rely on the error-free
HR pathway (Arnaudeau et al., 2001). In the absence of func-
tional BACH1, HR is defective; thus, these crosslinked replica-
tion forks may persist and be lethal. Deficiencies for other pro-
teins involved in HR, including BRCA1, BRCA2, and Rad51, all
result in hypersensitivity to MMC (Moynahan et al., 2001; Stark
et al., 2002; Yun et al., 2005). The repair of DNA interstrand
crosslinks, which are induced by MMC, is a multistep process
(Niedzwiedz et al., 2004). Translesion synthesis (TLS) and HR
appear to cooperate in repair of crosslinks (Hochegger et al.,
2004), and one way in which HR may be involved is in restart-
ing the replication fork following resolution of the damage
(Niedzwiedz et al., 2004). It has been reported that FANCC is
epistatic with TLS in chicken DT40 cells (Niedzwiedz et al.,
2004). This would suggest that the upstream FA pathway, cul-
minating in FANCD2 monoubiquitination, might have only a
modest role in HR (Nakanishi et al., 2005), with a greater role
in TLS. In contrast, the downstream FA pathway functioning
after FANCD2 monoubiquitination may be directly involved in
HR. This is best supported by the direct role of BRCA2/
FANCD1 in HR. Our paper’s findings now place BACH1, which
appears to be FANCJ, directly in the HR pathway as well. At
present, it is unknown whether the upstream pathway leading
to FANCD2 monoubiquitination simply regulates the involve-
ment of the downstream FA proteins in HR, or whether it has
a distinct function that precedes HR.
Transient or prolonged suppression of BACH1 in multiple tis-
sue culture cells, including human mammary epithelial cells, in
most cases led to increased or unchanged cell numbers com-
pared to BRCA1 siRNA or siRNA controls (S.B.C., unpub-
lished). The ability of cells to tolerate prolonged BACH1 defi-
ciency in tissue culture cells suggests that BACH1 function is
not required for proliferation or viability. Since the extreme HR
defect in BACH1-deficient cells does not affect cell viability, the
cells must be able to process DSBs by alternative pathways.
The identification of BACH1 mutations in breast cancer pa-
tients (Cantor et al., 2001) highlighted the possibility that
BACH1 is a tumor suppressor. The finding that BACH1 likely is
the gene defect in FA-J patients not only links BACH1 to the
FA pathway, but also indicates that BACH1 function is critical
for normal human development as well as for disease preven-
tion. Patients in the FA-J complementation group have several
symptoms, including café-au-lait spots, thumb abnormalities,
abnormal kidney, microphthalmia microcephaly, growth delay,261
A R T I C L Eand aplastic anemia, which are typical of other FA complemen-
tation groups (Levitus et al., 2004). Since such patients typi-
cally die at an early age, it is unknown whether breast cancer
would have developed.
Our findings suggest that BACH1 function is intimately linked
to maintenance of chromosome stability and HR. The HR DNA
repair defect reported here and previously reported checkpoint
defects (Yu et al., 2003) found in BACH1-deficient cells could
set the stage for genomic instability and eventual transforma-
tion. Therefore, we predict that BACH1 will be targeted in multi-
ple cancer syndromes in addition to breast cancer. This predic-
tion was borne out by the connection of BACH1 to FA, an
autosomal recessive disorder that encompasses a range of
cancer syndromes including leukemia, sarcoma, and medul-
loblastoma (Alter, 2003). Interestingly, while kindred heterozy-
gous for BRCA2 mutations are predisposed to breast cancer,
FA-D1 patients with biallelic mutations of BRCA2 develop early
onset leukemia (Wagner et al., 2004). Given the prior associa-
tion of BACH1 mutations with breast cancer (Cantor et al.,
2001), this suggests the possibility that FA-J patients with bial-
lelic mutations of BACH1 will similarly have a different tumor
spectrum than that of heterozygous carriers. Future experi-
ments using mouse models or human cancer molecular genet-
ics will ideally reveal the true role of BACH1 in tumor sup-
pression.
Experimental procedures
Homologous recombination assay and DNA constructs
The plasmid, pDR-GFP, utilizes two modified GFP genes to create a recom-
bination reporter. The I-Sce1-GFP gene is a GFP gene that is mutated by
an 11 bp substitution to contain the 18 bp recognition sequence for the
I-Sce1 endonuclease. Downstream of I-Sce1-GFP is the 0.8 kb GFP frag-
ment iGFP, which is a wild-type GFP gene truncated at both its 5# and 3#
ends. Expression of I-Sce1 in cells that contain the pDR-GFP substrate
integrated into their genome results in a DSB in the chromosome at the
position of the I-Sce1 site. Repair of the induced DSB in I-Sce1-GFP by a
noncrossover gene conversion with iGFP reconstitutes a functional GFP
gene, expression of which can be scored by cellular fluorescence. Although
other DSB repair events at the I-Sce1 site are possible, they are not de-
tected, because the 11 bp substitutions in the I-Sce1-GFP gene cannot be
restored to the wild-type GFP sequence except through a templated gene
conversion event. Molecular analysis of the pDR-GFP substrate in sorted
GFP-positive cells after I-Sce1 expression has verified that cellular green
fluorescence, as measured by flow cytometry, results from repair by gene
conversion (Pierce et al., 1999). MCF7 DR-GFP cells were generated by
transfectingw1 × 106 MCF7 cells in a 100 mm dish with 4 g DNA plasmid
(pDR-GFP) with lipofectamine and Plus reagents (Invitrogen) following the
manufacturer’s guidelines. After 24 hr, cells were split into fresh dishes at
different cell densities. After 48 hr, fresh media containing 1.0 g/ml puro-
mycin was added to select for puromycin-resistant colonies.
MCF7 DR-GFP stable cells were seeded at low density and transfected
with either siRNA directed against BACH1 (Reagent A, 5# AGCUUACCCG
UCACA 3#, or Reagent B, 5# GUACAGUACCCCACCUUAU 3#), BRCA1
(siRNA BRCA1 pool, Dharmacon), or a luciferase control (Dharmacon).
Twenty-four hours after siRNA transfection, cells were transfected (Fugene)
with 10 g of the pCMV-I-Sce1 vector. Cells were collected 3–4 days fol-
lowing the final transfection and analyzed by flow cytometry. In each case,
the percentage of GFP-positive cells was scored out of a total of 250,000
total viable events. The shRNA lentiviral vectors were made by placing the
BACH1 (A) sequence and the BRCA1 sequence (5# AGTACGAGATTTAGT
CAAC) into the FSIPPW lentiviral vector as described previously (Kanello-
poulou et al., 2005).
MMC sensitivity assay and chromosome spreads
MCF7 cells were transiently transfected as described above. Twenty-four
hours after transfection, cells were seeded onto 96-well plates at 1 × 103262cells per well, incubated overnight, and then treated with a concentration
range of MMC (Sigma). After incubation for 4 to 5 days, the percent growth
was measured photometrically in a model 3550 microplate reader (Perkin
Elmer) as the relative growth (in luciferase units) using the Cell Titer glo-
viability assay (Promega). For quantitation, the luciferase units of each well
were normalized to those obtained from untreated cells assumed to yield
100% cell survival, and were normalized to those obtained from a well with-
out any cells, assumed to yield 0%.
Human mammary epithelial cells (HMEC) were infected with either eGFP
or BACH1 (A) shRNA (see description above), treated with 0.05 g/ml col-
cemid (Sigma), and incubated at 37°C for 1 hr. Cells were collected, resus-
pended in 75 mM KCl, and incubated in a 37°C water bath for 18 min.
Swollen cells were then fixed in 3:1 acetic acid and methanol for 45 min on
ice. The final fixation was repeated, and fixed cells were dropped on cover-
slips, exposed to steam from an 80°C water bath, and dried cell-side-up
on a 70°C heat block. Coverslips were stained with 0.3 g/ml propidium
iodide for 30 min, washed for 30 min, and mounted on glass slides. Meta-
phase spreads were captured using an Olympus IX 70 Inverted Light micro-
scope. Data were collected as a Z series for deconvolution with 0.2 m
between planes. Images were deconvolved using MetaMorph software, no
neighbors algorithm.
Cell culture
MCF7 cells were cultured in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (Gibco) and antibiotics. MCF7
DR-GFP, FA-A fibroblasts (PD6914 + pMMP empty vector), FA-A reconstitu-
ted fibroblasts (PD6914 + FANCA), and FA-D2 fibroblasts (PD20) were
grown as above with the addition of 1 g/ml puromycin. MCF7-DR-GFP
cells, resistant to puromycin, were screened for the ability to show I-SceI
induction of HR, since pooled populations would contain a number of cells
that would not contribute to the HR assay. Normal human skin fibroblasts
(PD846F) (Andreassen et al., 2004) and FA-J fibroblasts (AG656) (Levitus et
al., 2004) immortalized with hTERT were grown in DMEM supplemented
with 15% FBS and antibiotics.
Immunoprecipitation and Western blot assays
Cells were harvested and lysed in lysis buffer (20 mM Tris [pH 8.0], 150 mM
NaCl, 1 mM EDTA, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, 10
g/ml leupeptin, 10 g/ml aprotinin) for 30 min on ice. For FANCD2 mono-
ubiquitination assays, cells were treated with 1 mM HU (Sigma) for 24 hr
and lysed as above, but with 600 mM NaCl. Cell extracts were clarified by
centrifugation for 10 min at 13,200 rpm. The cell lysates were boiled in
SDS loading buffer and DTT. For precipitation assays, cells lysates were
incubated with either protein A beads for I82 and E67 Abs, or with glutathi-
one-conjugated beads for BRCT-GST fusion protein, and incubated at 4°C
for 2 hr. Beads were subsequently washed and boiled in SDS loading buffer.
Proteins were separated using SDS-PAGE and electrotransferred to nitro-
cellulose membranes.
Western blot assays were carried out with several Ab reagents. To detect
BRCA1, the BRCA1 monoclonal Ab (MS110) was used. To detect BACH1,
the monocolonal Ab pool including 1A3, 2G7, and IG5 (Cantor et al., 2001)
or the polyclonal Abs I82 (a gift of R. Drapkin), E67 (Cantor et al., 2004),
and E87 (see Figure S2) were used. Additionally, β-actin (Sigma) monoclonal
Ab and E35 rabbit anti-human FANCD2 antibody (Garcia-Higuera et al.,
2001) were used. Primary Abs were incubated for 2 hr at 4°C. Primary anti-
bodies were detected with horseradish peroxidase-conjugated secondary
antibodies (Amersham Biosciences) for 1 hr at RT. All blots were detected
with ECL-plus Western Blotting Detection System (Amersham Biosciences)
using Biomax MR or XAR film (Kodak). Bradford assays were used to deter-
mine protein content (Bio-Rad).
Immunofluorescence microscopy
Cells were fixed with 2% paraformaldehyde in PBS for 20 min at RT, and
were subsequently permeabilized with 0.2% Triton X-100 in PBS for 3 min
at RT, and incubations with antibodies and washes were as previously de-
scribed (Cantor et al., 2001). For immunostaining of γ-H2AX or Rad51,
MCF7 or FA-J cells were treated with 1 mM HU for 18 hr and stained as
above. Mouse monoclonal anti-phospho-Histone γ-H2AX (Ser139) anti-
bodies were purchased from Upstate. Polyclonal Rad51 Abs were pur-
chased from Santa Cruz. Secondary Abs were either Rhodamine Red-con-CANCER CELL : SEPTEMBER 2005
A R T I C L Ejugated AffiniPure Goat anti-mouse IgG or FITC-conjugated AffiniPure Goat
Anti-rabbit IgG purchased from Code Jackson ImmunoResearch Laborato-
ries Inc.
Sequencing
Total RNA was purified from FA-J cells (Qiagen RNeasy), and RT-PCR was
performed as outlined by the manufacturer (Qiagen one-step RT-PCR) using
overlapping primers. The thermocycling conditions for amplification of
cDNA were as follows: 50° for 30 min, 95° for 15 min, 40 cycles each with
a denaturing step at 94°C for 1 min, an annealing step at 50°C for 1 min,
and an extension step at 72°C for 1 min. The reaction was completed with
a final extension at 72°C for 10 min and a 4°C soak. Genomic DNA was
purified from FA-J cells (Qiagen DNeasy), and PCR was performed using
intronic primers that flank the mutated region observed in exon 17. The
thermocycling conditions for amplification of genomic DNA were as follows:
95°C for 2 min, followed by 30 cycles each with a denaturing step at 95°C
for 30 s, an annealing step at 50°C for 1 min, and an extension step at 72°C
for 4 min. The reaction was completed with a final extension at 72°C for 10
min and a 4°C soak. Both RT-PCR and PCR products were separated on
1% agarose gels containing ethidium bromide and visualized with UV light.
PCR primer combinations were as follows (primers written in 5#-3# orien-
tation):
A#: CCGCTTTATTTGCTCTCAGAAG and CTGTTCCAAAGCAATGACGTT
TTCTAATCTGCTGT;
A: ATGTCTTCAATGTGGTCTGAATATACAATT and ACACAGCCCGAGAAC
TAATACAA
B: TTGCTAGATGGGAAAAACGG and AGAGATTCCGACCCTTGGGGCC
C: GTTGGTACCATTGGGTCAGGC and TGATCTCCGCCCGTTTCAAAA
D: ACAAAGAGAGTTAGCTGGTCAAGCTTTA and CAGCGGCCGCCTT
AAAACCAGGAAACATGCCTTTATT




PCR products were sequenced (Nucleic Acid Facility, UMMS) on both
strands with the primers used to create the amplicon. Additional primers






Lentiviral infection and G2/M accumulation assay
FA-J cells were infected with either pLENTI6/v5-DEST (Invitrogen) empty
vector or pLENTI6/v5-DEST + WT BACH1 (gift of J. Chen), and stable cells
were selected with 7 g/ml Blasticidin (Invitrogen). PD846F (Normal), FA-J,
FA-J + vector, and FA-J + WT BACH1 cells immortalized with hTERT were
either mock treated or treated with 0.5 g/ml of melphalan (Sigma) and
incubated for 65 hr. Cells were fixed with 90% methanol in PBS and were
then incubated 10 min with PBS containing 30 U/ml DNase-free RNase A
and 50 g/ml propidium iodide. 1 × 104 cells were analyzed using a Facs-
Calibur instrument (Becton-Dickinson, San Jose, CA). Aggregates were
gated out and the percentage of cells in G2/M was calculated using
FlowJo software.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/8/3/255/DC1/.
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